In 2013, Formation Bio was founded with a clear mission: to bring new treatments to patients faster and more efficiently. The founders recognized a critical bottleneck in drug development - while biotech innovation and AI were generating new drug candidates at an unprecedented pace, the process of developing these drugs was becoming exponentially more expensive and time-consuming. This widening gap between scientific discovery and patient access needed to be bridged.
Formation Bio began as TrialSpark, initially focused on building clinical trial technology tools and operating as a CRO before evolving to acquire and develop its own drug portfolio. In December 2023, the company rebranded to Formation Bio to reflect its expanded vision. Today, the company operates as an AI-native pharma company that acquires clinical-stage drugs from pharmaceutical companies, universities, and biotech firms, developing them through a proprietary technology platform. By bringing together the best of tech and pharma - deep expertise in drug selection, drug development, and software engineering - Formation Bio optimizes all aspects of clinical drug development. The company integrates AI and data-driven approaches across the entire development lifecycle, from drug acquisition to NDA submission, enabling more efficient trial design, faster trial completion, and higher quality data capture.